ArticleCost effectiveness and resource allocation : C/E2017
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
Article in Cost effectiveness and resource allocation : C/E, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- The structural and organizational aspects of human papillomavirus vaccine affecting immunization coverage in Europe: a systematic review.BMC public health · 2025Pooled it
- Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis.BMC public health · 2020Pooled it
- Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.PloS one · 2020Pooled it
- Public Health Impact and Cost-Effectiveness of Routine and Catch-Up Human Papillomavirus Vaccination in Girls and Women in Selected Regions of China: A Model-Based Study.PharmacoEconomics · 2026Article
- Methodological drivers, reporting completeness, and transferability in HPV vaccination economic evaluations: A scoping review.PloS one · 2026Article
- A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.Human vaccines & immunotherapeutics · 2025Article
- Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea.Human vaccines & immunotherapeutics · 2025Article
- Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.BMC medicine · 2025Article
- Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan.PloS one · 2025Article
- Human Papilloma Virus Vaccination and Cervical Screening in the Italian Regions: An Overview of the Current State of the Art.Vaccines · 2024Article
- Fine-grained mathematical modeling for cost-effectiveness evaluation of public health policies for cervical cancer, with application to a Colombian case study.BMC public health · 2023Article
- Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.Human vaccines & immunotherapeutics · 2023Article
- Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China.Frontiers in immunology · 2023Article
- Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.Human vaccines & immunotherapeutics · 2022Article
- Factors Influencing Men's Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program.Vaccines · 2022Article
- The impact of vaccination on human papillomavirus infection with disassortative geographical mixing: a two-patch modeling study.Journal of mathematical biology · 2022Article
- Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Italy HPV vaccination with the quadrivalent vaccine (Gardasil
methodsA dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies. The analyses compared two strategies with the nine-valent vaccine (cervical cancer screening and vaccination in girls only or vaccination in boys and girls) to four alternative strategies (cervical cancer screening and vaccination with quadrialent vaccine in girls only, in both boys and girls, with bivalent vaccine in girls and screening strategy only). The National Health Service perspective was considered.
conclusionThe switch to the nine-valent vaccine in Italy can further reduce the burden associated to cervical cancer and HPV-related diseases and is highly cost-effective.
resultsCompared to the current vaccination program with quadrivalent vaccine, the nine-valent vaccine in a programme including girls and boys shows further reductions of 17% in the incidence of cervical cancer, 35 and 14% in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years. The new technology is associated with an ICER of 10,463€ per QALY gained in universal vaccination, decreasing to 4483€ when considering the vaccine switch for girls-only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.